Celltrion (068270) Investor Presentation summary

Business overview and growth trajectory

• Achieved a 30% CAGR in revenue since 2002, driven by biosimilar launches and global expansion.

• Established direct sales networks in the EU (2019) and US (2023), broadening market presence.

• In-house production capacity of 250,000L supports large-scale manufacturing and global supply.

• Commercialized multiple biosimilars and novel drugs, targeting 22 products by 2030.

Biosimilar portfolio and market position

• One of only four companies globally with annual biosimilar sales over $1 billion.

• Maintains strong market share: 60% in Europe and double the US share of competitors for Remsima/Inflectra.

• Remsima SC achieved 24% market share in EU5, with combined IV+SC share at 76%.

• Yuflyma and Vegzelma sales in Europe have more than doubled year-over-year, driven by successful bid strategies.

• Truxima and Herzuma continue to gain share globally, with Herzuma holding ~70% in Japan.

Novel drug innovation and pipeline

• Transitioned from biosimilar leader to innovator, developing the world’s first mAb biosimilar and novel antibody drugs.

• ADC and multispecific antibody pipelines advancing, with multiple IND submissions planned for 2025–2026.

• CT-P70 and CT-P71 demonstrated superior preclinical efficacy at World ADC 2024, with Phase 1 INDs planned.

• Zymfentra, the first and only subcutaneous infliximab, offers high efficacy, patent protection to 2040, and rapid US market penetration.

• Zymfentra’s prescription volume and sales are growing, supported by major PBM formulary listings and positive clinical data.